



Press Release

September 14, 2009

Stock offering for Faron shareholders provided €1.25 millions of new capital for Traumakine-program

Based on the annual shareholders' resolution, Faron Board has decided to offer new shares for the current Faron shareholders. This offer has resulted in orders that has provided €1.25 millions of new capital for the Company. Faron had previously indicated that the new capital is used solely to the expansion of the Traumakine program, which is currently in phase I/II clinical study in UK. Traumakine is meant to treat acute lung injury (ALI) and a related condition called ARDS. Today's mortality rates for these conditions are 35 and 60 percent, respectively. Currently there is no pharmacological treatment available for ALI/ARDS, and therefore these conditions kill annually as many people as asthma, breast cancer and HIV infection.

- Faron's Traumakine program is advancing very well and with this additional capital we can secure our near term goals of that program, comments Faron's President and CEO **Markku Jalkanen**. We want to finish our UK phase I/II trial as soon as possible, hopefully allowing Faron to move to pan-European pivotal trial within the next 1-2 years, concludes Jalkanen.

Faron Pharmaceuticals, Ltd. is a virtual drug discovery and development company with three major drug development projects, targeting CD73, Clever-1 and AOC3 molecules and focusing on indications such as acute traumas, incipient vasculopathies, inflammatory diseases and cancer metastasis.

For further information please contact:

Markku Jalkanen, CEO
Phone: +358-40-520-6124
E-mail: markku.jalkanen@faronpharmaceuticals.com
www.faronpharmaceuticals.com